Artículos por temáticas

Ketogenic diet in the management of disease

Luong T, Svart M, Gormsen LC, Søndergaard E.

Curr Opin Clin Nutr Metab Care. 2025 Nov 1;28(6):477-482. doi: 10.1097/MCO.0000000000001158. Epub 2025 Aug 7.

Kynurenine pathway in Parkinson's disease: pathophysiological roles and therapeutic interventions

Chakraborty A, Chaudhary P, Das J, Bhui U, Aran KR, Hussain MS, Ashique S, Debnath B.

Inflammopharmacology. 2025 Nov 27. doi: 10.1007/s10787-025-02052-x. Online ahead of print.

Sleep deprivation and risk for Parkinson's disease: evidence and therapeutic implications

Zhou T, Ye W, Chen B, Zhu L, Wang Z, Mao J, Wu W, Li Y, Wu H.

J Neurol. 2025 Oct 30;272(11):740. doi: 10.1007/s00415-025-13407-3.

Treatment options for depression in Parkinson's disease: a mini-review

Raggi A, Serretti A, Ferri R.

Int Clin Psychopharmacol. 2025 Nov 1;40(6):312-320. doi: 10.1097/YIC.0000000000000588. Epub 2025 Mar 13.

DJ-1/PARK7 in Parkinson's disease: mechanisms of pathogenesis and therapeutic potential

Bao W, Ge Y, Huang J, Li Y, Luo Y, Huang N.

Neuroscience. 2025 Nov 10;587:1-13. doi: 10.1016/j.neuroscience.2025.09.025. Epub 2025 Sep 19.

Current therapeutic strategies in Parkinson's disease: Future perspectives

Kim TY, Lee BD.

Mol Cells. 2025 Nov;48(11):100274. doi: 10.1016/j.mocell.2025.100274. Epub 2025 Sep 4.

Trichloroethylene Exposure and Parkinson's Disease: Environmental Risk, Metabolic Pathways, and Mechanistic Insights

Liu R, Zhang F, Lou J, Song F.

Mol Neurobiol. 2025 Dec;62(12):15336-15348. doi: 10.1007/s12035-025-05172-1. Epub 2025 Jul 4.

LRRK2 Degraders for Parkinson's Disease and Inflammation: Tau and α‑Synuclein Degraders for Neurodegeneration

Renner AC, Kargbo RB.

ACS Med Chem Lett. 2025 Oct 10;16(11):2171-2174. doi: 10.1021/acsmedchemlett.5c00594. eCollection 2025 Nov 13.

Cerebrospinal fluid biomarkers for diagnosis of Parkinson's disease: a systematic review and network meta-analysis

Li S, Yang C, Wu J, Zheng Y, Yu Z, Liu G, Yang Y, Feng T.

J Neurol. 2025 Dec 1;272(12):793. doi: 10.1007/s00415-025-13546-7.

Addressing sexual difficulties in Parkinson's disease

Oprea E.

Rev Neurol (Paris). 2025 Oct 31:S0035-3787(25)00620-4. doi: 10.1016/j.neurol.2025.10.004. Online ahead of print.

Dysphagia and oropharyngeal bradykinesia in Parkinson's disease

Stocchi F, Annese E, Radicati F, Alborghetti M.

J Neural Transm (Vienna). 2025 Nov;132(11):1665-1671. doi: 10.1007/s00702-025-03045-4. Epub 2025 Oct 21.

The microbial guardians: Unveiling the role of gut microbiota in shaping neurodegenerative disease

Abou Izzeddine N, Ahmad K, Bacha C, Jabbour M, Najjar M, Salhab S, Ghadieh HE, Kanaan A, Azar S, Khattar ZA, Harb F.

IBRO Neurosci Rep. 2025 May 30;19:17-37. doi: 10.1016/j.ibneur.2025.05.014. eCollection 2025 Dec.

Neuroregulatory effect of royal jelly

Zhu F, Yang R, He B, Xu Y, Wang HL.

J Nutr Biochem. 2025 Nov;145:110028. doi: 10.1016/j.jnutbio.2025.110028. Epub 2025 Jul 11.

Voice-Based Detection of Parkinson's Disease Using Machine and Deep Learning Approaches: A Systematic Review

Sedigh Malekroodi H, Lee BI, Yi M.

Bioengineering (Basel). 2025 Nov 20;12(11):1279. doi: 10.3390/bioengineering12111279.

Golexanolone Attenuates Neuroinflammation, Fatigue, and Cognitive and Motor Impairment in Diverse Neuroinflammatory Disorders

Llansola M, Mincheva G, Arenas YM, Izquierdo-Altarejos P, Pedrosa MA, Blackburn TP, Bäckström T, Scharschmidt BF, Doverskog M, Felipo V.

Pharmaceuticals (Basel). 2025 Nov 18;18(11):1757. doi: 10.3390/ph18111757.